Zoekresultaten - 24 results
Annual Report Belgian Cystic Fibrosis Registry 2018
Pseudomonas aeruginosa reported in 2018 was 37.9%. This is in line with the general decline observed from 42.4% in 2012 to 37.5% in 2016. There has also been a steady increase in the prevalence of Achromobacter ...
Annual Report Belgian Cystic Fibrosis Registry 2017
2010 and 54.8% and 11.3% respectively among the children and adults in 2017. The overall annual prevalence of Pseudomonas aeruginosa reported in 2017 was 39.1%. This is the first time the prevalence has ...
Annual report Belgian Cystic Fibrosis Registry 2016
and 13.6% respectively among the children and adults in 2016. The overall annual prevalence of Pseudomonas aeruginosa reported in 2016 was 37.5% and has been declining compared to a prevalence of 42.4% ...
Surveillanceprogramma van septicemieën in ziekenhuizen in België- Gegevens 2000-2011
(11%). The specific incidence of hospital acquired SEP with E. coli increased from 1,2/10.000 pd in 2000 to 1,7/10.000 pd in 2011. The specific incidence of hospital acquired SEP caused by Pseudomonas ...
A multifaceted study of Pseudomonas aeruginosa shutdown by virulent podovirus LUZ19
quantitative PCR (qPCR), microarray, RNA-seq, and two-dimensional gel electrophoresis (2D- GE), to obtain a global overview of alterations in DNA, RNA, and protein content in Pseudomonas aeruginosa PAO1 cells ...
Surveillance van antibioticaresistente bacteriën in Belgische ziekenhuizen: jaarrapport 2011
Keywords: Acinetobacter baumannii Belgische CPE ESBL MRE MRSA Pseudomonas aeruginosa Surveillance ziekenhuizen Abstract: NA Health Topics: Antimicrobiële resistentie (AMR) Résistance aux antimicrobiens (AMR) ...
Programme de surveillance des septicémies à l’hôpital en Belgique, Données 2000-2011
hospital acquired SEP caused by Pseudomonas aeruginosae and Klebsiella pneumoniae remained stable. These incidence data are higher than those reported by the surveillances (hospitalwide) from other ...
Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy87
Patient patients Pharmacokinetic pharmacokinetics plasma Pseudomonas Pseudomonas aeruginosa RANGE RENAL Renal Replacement Therapy Replacement therapy result Sample Samples SB- IM serum Shock,Septic study ...
Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study.
health-care-associated infections. We focused on the most frequent causative microorganisms. Resistance was defined as resistance to ceftazidime (Acinetobacter baumannii or Pseudomonas aeruginosa), third-generation ...
Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock
Pseudomonas Pseudomonas aeruginosa Research Research Support result results Sepsis serum Shock,Septic study Target therapeutic use Thienamycins time treatment WHO Abstract: INTRODUCTION: Altered ...